TITLE:
A Study of ABT-751 in Patients With Renal Cell Cancer

CONDITION:
Renal Cell Cancer

INTERVENTION:
ABT-751

SUMMARY:

      The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how
      long the tumor shrinkage can be maintained in patients with renal cell cancer. Patients will
      receive ABT-751 by mouth daily for 21 days. Patients will be off drug for 7 days before
      starting the next cycle of drug.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria

          -  Renal Cell Carcinoma.

          -  Recurrent tumor.

          -  At least 6 weeks post-nephrectomy.

          -  Able to tolerate normal activities of daily living.

          -  Adequate bone marrow, kidney, and liver function.

        Exclusion Criteria

          -  Pregnant or breast feeding.

          -  Anti-tumor therapy within 4 weeks of the start of ABT-751 administration.

          -  CNS metastasis.
      
